Resultados da pesquisa - Mark J. Chicarelli
- A mostrar 1 - 2 resultados de 2
-
1
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity Por Jay B. Fell, John P. Fischer, Brian R. Baer, Joshua A. Ballard, James F. Blake, Karyn Bouhana, Barbara J. Brandhuber, David M. Briere, Laurence E. Burgess, Michael Burkard, Harrah Chiang, Mark J. Chicarelli, Kevin Davidson, John J. Gaudino, Jill Hallin, Lauren Hanson, Kenneth Hee, Erik J. Hicken, Ronald J. Hinklin, Matthew A. Marx, Macedonio J. Mejia, Peter Olson, Pavel Y. Savechenkov, Niranjan Sudhakar, Tony P. Tang, Guy Vigers, Henry Zecca, James G. Christensen
Publicado em 2018Artigo -
2
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer Por Jay B. Fell, John P. Fischer, Brian R. Baer, James F. Blake, Karyn Bouhana, David M. Briere, Karin Brown, Laurence E. Burgess, Aaron C. Burns, Michael Burkard, Harrah Chiang, Mark J. Chicarelli, Adam W. Cook, John J. Gaudino, Jill Hallin, Lauren Hanson, Dylan P. Hartley, Erik J. Hicken, Gary P. Hingorani, Ronald J. Hinklin, Macedonio J. Mejia, Peter Olson, Jennifer Otten, Susan P. Rhodes, Martha E. Rodriguez, Pavel Y. Savechenkov, Darin Smith, Niranjan Sudhakar, Francis X. Sullivan, Tony P. Tang, Guy Vigers, Lance Wollenberg, James G. Christensen, Matthew A. Marx
Publicado em 2020Artigo